Alpha-synuclein Level in Saliva to Differentiate Between Idiopathic Parkinson Disease and Iatrogenic Parkinsonian Syndrome

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine whether a significant reduction in the total level of alpha-synuclein and significant increase in the oligomeric form of alpha-synuclein and therefore the ratio oligomeric:total alpha-synuclein occurs in patients with Parkinson disease compared to patients with drug-induced parkinsonian syndrome.

Official Title
-----------------
Alpha-synuclein Level in the Saliva as a Potential Diagnostic Aid to Differentiate Between Idiopathic Parkinson Disease and Iatrogenic Parkinsonian Syndrome

Conditions
-----------------
Parkinson Disease, Parkinsonian Disorders

Intervention / Treatment
-----------------
* Diagnostic Test: Level of alpha-synuclein


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria The patient must have given their free and informed consent and signed the consent form The patient must be insured or the beneficiary of an insurance policy The patient is less than 55 years old For patients with acquired parkinsonian syndrome (UKPDSBB criteria) currently at HOEHN and YAHR stage ≤3: For patients recruited via a psychiatrist: after anti-dopamine treatment For patients recruited via a neurologist: having a recent diagnosis (≤2 years) of Parkinson disease Exclusion Criteria: The subject is participating in another study The subject is in an exclusion period determined by a previous study The patients is under judicial protection The subject or their representative refused to sign the consent form It proves impossible to give the subject or their representative clear information. Patients with atypical degenerative parkinsonian syndrome Patients with vascular, post-traumatic, metabolic, toxic or genetic parkinsonian syndrome Appearance of parkinsonian syndrome prior to treatment with anti-dopamine Injection of botulinum toxin into the salivary glands Contra-indication on DAT-scan (unbalanced dysthyroidism, allergy, treatment with bupropion or amphetaminergics) Poor oral health (polyposis, gingivostomatitis) observed during the odontologist visit Patients not taking anti-psychotics with parkinsonian syndrome and normal DAT-scan

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| idiopathic Parkinson disease<br> | Diagnostic Test: Level of alpha-synuclein<br>* Test of levels of total and ratio total:oligomeric in saliva<br>|
| iatrogenic parkinsonian syndrome<br> | Diagnostic Test: Level of alpha-synuclein<br>* Test of levels of total and ratio total:oligomeric in saliva<br>|
| healthy volunteers<br> | Diagnostic Test: Level of alpha-synuclein<br>* Test of levels of total and ratio total:oligomeric in saliva<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare saliva level of oligomeric alpha-synuclein between two groups of patients wth classical parkinsonian: patients with idiopathic Parkinson disease and patients with a acquired parkinsonian syndrome from anti-dopamine treatment. |  | Day 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perform the first estimation of discriminatory capacity of saliva levels of oligomeric alpha-synuclein for diagnostic differentiation between idiopathic Parkinson disease and anti-dopamine induced acquired parkinsonian syndrome. |  | Day 0 | 
| Compare levels of total alpha-synuclein and the ratio of oligomeric alpha-synuclein:total alpha-synuclein between the two groups |  | Day 0 | 
| Perform the first estimation of discriminatory capacity of saliva levels of total oligomeric alpha-synuclein and the ratio of oligomeric alpha-synuclein:total alpha-synuclein for diagnostic differentiation between two groups |  | Day 0 | 
| Creation of a biobank with remaining samples | saliva samples | Day 0 | 
| UPDRS II-III-IV score |  | Day 0 | 
| UDysRs score |  | Day 0 | 
| character of parkinsonian syndrome | symmetrical or asymmetrical | Day 0 | 
| akathisia |  | Day 0 | 
| questionnaire on non-motor symptoms in Parkinson disease | PD-NMS | Day 0 | 
| neuro-psychological evaluation | BREF+MOCO score | Day 0 | 
| GDS score |  | Day 0 | 
| interogation to determine extent of motor and non-motor clinical markers to differentiate the two groups |  | Day 0 |